Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, May 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 276 articles:
HTML format


 

Single Articles

  1. GAUTAM KA, Raghav A, Sankhwar SN, Singh R, et al
    Genetic Polymorphisms of Gene Methionine Synthase Reductase (MTRR) and Risk of Urinary Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:1137-1141.
    PubMed    
    Abstract available

  2. ECKE TH, Wirtz RM, Friedersdorff F, Fussel S, et al
    [Research in bladder cancer: translation into the clinic-report of 13th annual meeting of the German Research Group on Bladder Cancer (DFBK) in Berlin].
    Urologie. 2023 Apr 28. doi: 10.1007/s00120-023-02093.
    PubMed    


  3. PENG C, Guo S, Yang Z, Li X, et al
    A prognostic model for bladder cancer based on cytoskeleton-related genes.
    Medicine (Baltimore). 2023;102:e33538.
    PubMed    
    Abstract available

  4. WU M, Zheng X, Wang X, Li X, et al
    The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study.
    Cancer Control. 2023;30:10732748231173475.
    PubMed    
    Abstract available

  5. AL-AZAB R, Al-Zubi M, Al Demour S, Khaled Al-Jamal S, et al
    Adherence to guidelines in the follow-up of non-muscle-invasive bladder cancer among urology trainers and trainees in Jordan: a cross-sectional study.
    Ann Med Surg (Lond). 2023;85:763-766.
    PubMed    
    Abstract available

  6. KANG Y, Park C, Lee H, Kang S, et al
    Natural Products as New Approaches for Treating Bladder Cancer: From Traditional Medicine to Novel Drug Discovery.
    Pharmaceutics. 2023;15:1117.
    PubMed    
    Abstract available

  7. ZHANG-YIN J, Girard A, Marchal E, Lebret T, et al
    PET Imaging in Bladder Cancer: An Update and Future Direction.
    Pharmaceuticals (Basel). 2023;16:606.
    PubMed    
    Abstract available

  8. WILCZAK M, Surman M, Przybylo M
    Altered Glycosylation in Progression and Management of Bladder Cancer.
    Molecules. 2023;28:3436.
    PubMed    
    Abstract available

  9. HU B, Chen R, Jiang M, Xiong S, et al
    MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer.
    Int J Mol Sci. 2023;24:7608.
    PubMed    
    Abstract available

  10. ZHU J, Tong H, Sun Y, Li T, et al
    YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.
    Int J Mol Sci. 2023;24:6905.
    PubMed    
    Abstract available

  11. PANEBIANCO V
    VI-RADS for the diagnosis and management of urinary bladder cancer.
    Eur Radiol. 2023 Apr 28. doi: 10.1007/s00330-023-09677.
    PubMed    


  12. WANG Y, Ju L, Wang G, Qian K, et al
    DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC.
    Nat Commun. 2023;14:2421.
    PubMed    
    Abstract available

  13. ROBERTSON AG, Meghani K, Cooley LF, McLaughlin KA, et al
    Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
    Nat Commun. 2023;14:2126.
    PubMed    
    Abstract available

  14. MAGEE DE, Cheung DC, Hird AE, Chung P, et al
    Cost of Bladder Cancer Care: A Single Centre Comparison of Radical Cystectomy and Trimodal Therapy.
    Urol Pract. 2023 Apr 4:101097UPJ0000000000000403.
    PubMed    
    Abstract available

  15. SORIA F, D'Andrea D, Barale M, Gust KM, et al
    Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guerin: Implications for Decision-making?
    Eur Urol Open Sci. 2023;50:17-23.
    PubMed    
    Abstract available

  16. FU Y, Liu K, Zhao L, Jiang X, et al
    Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496.
    Eur Urol Open Sci. 2023;50:31-42.
    PubMed    
    Abstract available

  17. LI J, Qi Y, Li B, Liu Y, et al
    STIL/AURKA axis promotes cell proliferation by influencing primary cilia formation in bladder cancer.
    J Transl Med. 2023;21:281.
    PubMed    
    Abstract available

  18. HOLTEDAHL K, Borgquist L, Donker GA, Buntinx F, et al
    Symptoms and signs of urogenital cancer in primary care.
    BMC Prim Care. 2023;24:107.
    PubMed    
    Abstract available

  19. ADAMS-MARDI C, Sparks A, Whalen M
    Impact of Minimally Invasive Approach to Radical Cystectomy in Bladder Cancer Patients with Malnutrition.
    Nutr Cancer. 2023 Apr 26:1-6. doi: 10.1080/01635581.2023.2202432.
    PubMed    
    Abstract available

  20. GU S, Yang C
    Serum lactate dehydrogenase level predicts the prognosis in bladder cancer patients.
    BMC Urol. 2023;23:65.
    PubMed    
    Abstract available

  21. LEONG SW, Wang J, Okuda KS, Su Q, et al
    Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces apoptotic and autophagic cell death in bladder cancer cells.
    Eur J Med Chem. 2023;254:115335.
    PubMed    
    Abstract available

  22. HAGGSTROM C, Rowley M, Liedberg F, Coolen ACC, et al
    Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe).
    Cancer Med. 2023 Apr 25. doi: 10.1002/cam4.5981.
    PubMed    
    Abstract available

  23. XU H, Lin T, Ai J, Zhang J, et al
    Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Bladder Cancer After Radical Cystectomy.
    J Inflamm Res. 2023;16:1733-1744.
    PubMed    
    Abstract available

  24. HALSTUCH D, Lotan P, Karchever I, Rubinshtein D, et al
    Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
    Clin Genitourin Cancer. 2023 Mar 23:S1558-7673(23)00066.
    PubMed    
    Abstract available

  25. LIN Y, Li T, Li Z, Shen C, et al
    Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
    Front Genet. 2023;14:1097179.
    PubMed    
    Abstract available

  26. JAMES C, Gomez K, Desai S, Patel HD, et al
    Impact of intravesical Bacillus Calmette-Guerin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer.
    Front Cell Infect Microbiol. 2023;13:1125809.
    PubMed    
    Abstract available

  27. ZHAO Y, Li M, Wu W, Miao W, et al
    Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization.
    Front Immunol. 2023;14:1161273.
    PubMed    
    Abstract available

  28. MARSH GM, Kruchten A
    A reevaluation of selected mortality risks in the updated NCI/NIOSH acrylonitrile cohort study.
    Front Public Health. 2023;11:1122346.
    PubMed    
    Abstract available

  29. JOYCE DD, Sharma V, Williams SB
    Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature.
    Pharmacoeconomics. 2023 Apr 23. doi: 10.1007/s40273-023-01273.
    PubMed    
    Abstract available

  30. WU Q, Zhang H, You S, Xu Z, et al
    NEDD4L inhibits migration, invasion, cisplatin resistance and promotes apoptosis of bladder cancer cells by inactivating the p62/Keap1/Nrf2 pathway.
    Environ Toxicol. 2023 Apr 23. doi: 10.1002/tox.23796.
    PubMed    
    Abstract available

  31. MODOS O, Varadi M, Der B, Keszthelyi A, et al
    [Current diagnostic and treatment strategies for urachal cancer].
    Orv Hetil. 2023;164:602-609.
    PubMed    
    Abstract available

  32. CAI T, Lu J, Lin Z, Lup M, et al
    [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
    Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:488-494.
    PubMed    
    Abstract available

  33. LU YT, Plets M, Morrison G, Cunha AT, et al
    Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
    Eur Urol Oncol. 2023 Apr 20:S2588-9311(23)00074.
    PubMed    
    Abstract available

  34. ASTUDILLO C, Garcia-Perdomo HA
    Electronic cigarette: is it a risk factor for the development of bladder cancer?
    Actas Urol Esp (Engl Ed). 2023 Apr 20:S2173-5786(23)00047.
    PubMed    


  35. CHEN N, Li P, Liu L, Zhang J, et al
    Cucurbitacin IIb Extracted from Hemsleya penxianensis Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells by Regulating Cell Cycle Checkpoints and Mitochondrial Apoptotic Pathway.
    Plant Foods Hum Nutr. 2023 Apr 22. doi: 10.1007/s11130-023-01058.
    PubMed    
    Abstract available

  36. YILDIZ AK, Ozgur BC, Bayraktar AS, Demir DO, et al
    How has the COVID-19 pandemic affected patients with primary bladder cancer?
    Cir Cir. 2023;91:204-211.
    PubMed    
    Abstract available

  37. YASUI M, Cui L, Miyamoto H
    Recent advances in the understanding of urothelial tumorigenesis.
    Expert Rev Anticancer Ther. 2023;23:485-493.
    PubMed    
    Abstract available

  38. SHERMAN E, Lee JL, Debruyne PR, Keam B, et al
    Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
    ESMO Open. 2023;8:100877.
    PubMed    
    Abstract available

  39. JING W, Chen C, Wang G, Han M, et al
    Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of Nanoporter-Encased Hydrogel Eradicates Bladder Carcinoma.
    Adv Sci (Weinh). 2023;10:e2206893.
    PubMed    
    Abstract available

  40. GUO J, Liang X, Zheng Y, Ma J, et al
    Progress in the treatment of urethral adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:2693-2698.
    PubMed    
    Abstract available

  41. SUN MY, Peng Y, Liu DW, Wang K, et al
    Ectopic prostate tissue at the bladder trigone accompanied by cystitis glandularis and hemorrhage detected by multiparametric MRI.
    Asian J Androl. 2023;25:438-439.
    PubMed    


  42. ABDELRAHMAN I, Aboulkassem H, Elazab A, Abdallah AY, et al
    Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    J Egypt Natl Canc Inst. 2023;35:13.
    PubMed    
    Abstract available

  43. REESINK DJ, van Melick HHE, van der Nat PB, Los M, et al
    Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
    World J Urol. 2023 May 5. doi: 10.1007/s00345-023-04408.
    PubMed    
    Abstract available

  44. DU KL, Ji WT, Jiang QH, Wang Y, et al
    Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
    Clin Lab. 2023;69.
    PubMed    
    Abstract available

  45. JIN Y, Li J, Tang C, He K, et al
    A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer.
    Medicine (Baltimore). 2023;102:e33664.
    PubMed    
    Abstract available

  46. NOVA-CAMACHO LM, Val-Carreres Castellote A, Villafruela Mateos A
    Xanthogranulomatous Ureteritis: A Diagnostic Challenge in a Patient with Bladder Cancer.
    Int J Surg Pathol. 2023 May 4:10668969231169049. doi: 10.1177/10668969231169049.
    PubMed    
    Abstract available

  47. JIANG YK, Situai YJ, Deng HM, Zhang H, et al
    ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
    Curr Med Sci. 2023 May 5. doi: 10.1007/s11596-023-2731.
    PubMed    
    Abstract available

  48. FAULK A, Avulova S, Bree KK, Baak-Kukreja J, et al
    Pelvic Organ Preservation in Non-muscle-invasive Bladder Cancer: Less Is More.
    Eur Urol Focus. 2023 May 2:S2405-4569(23)00103-7. doi: 10.1016/j.euf.2023.
    PubMed    
    Abstract available

  49. PLAIS H, Dumont C, Gauthier H, Culine S, et al
    Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.
    Immunotherapy. 2023 May 4. doi: 10.2217/imt-2022-0283.
    PubMed    
    Abstract available

  50. LI Q, Qing L, Xu W, Yang Y, et al
    Berberine Affects the Proliferation, Migration, Invasion, Cell Cycle, and Apoptosis of Bladder Cancer Cells T24 and 5637 by Down-Regulating the HER2/PI3K/AKT Signaling Pathway.
    Arch Esp Urol. 2023;76:152-160.
    PubMed    
    Abstract available

  51. OKUCU E, Yucetas U, Karsiyakali N, Koseoglu H, et al
    Higher Serum Endothelial-Specific Molecule-1 (ESM-1/Endocan) Levels are Associated with Poor Pathological Outcomes in Primary Bladder Cancer: A Non-randomized, Prospective, Case-Control Study.
    Arch Esp Urol. 2023;76:132-138.
    PubMed    
    Abstract available

  52. SANCHEZ VERDES P, Fernandez-Pello Montes S, Gonzalez Rodriguez I, Suarez Sal PJ, et al
    Impact of a One-Stop Hematuria Clinic on Overall Survival and Bladder Tumor Recurrence.
    Arch Esp Urol. 2023;76:114-122.
    PubMed    
    Abstract available

  53. LU Y, Jiang S, Yin X, Guo J, et al
    Long-term effect of transurethral partial cystectomy with a 2-micrometer continuous-wave laser for non-muscle-invasive bladder cancer.
    Front Surg. 2023;10:1117997.
    PubMed    
    Abstract available

  54. SHI ZD, Han XX, Song ZJ, Dong Y, et al
    Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression.
    Biomark Res. 2023;11:47.
    PubMed    
    Abstract available

  55. LONG F, Wang W, Li S, Wang B, et al
    The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer.
    J Transl Med. 2023;21:298.
    PubMed    
    Abstract available

  56. KAWADA T, Yanagisawa T, Bekku K, Laukhtina E, et al
    The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
    Urol Oncol. 2023 May 1:S1078-1439(23)00118-7. doi: 10.1016/j.urolonc.2023.
    PubMed    
    Abstract available

  57. MARTINS PR, Santos TPMD, Menezes LM, Froede AG, et al
    Association of human papillomavirus (HPV), p16, p53 and p63 expression with non-bilharzia-associated squamous cell carcinoma of the bladder and algorithm construction for histopathological grading prediction.
    Einstein (Sao Paulo). 2023;21:eAO0109.
    PubMed    
    Abstract available

  58. RASTI A, Khalili M, Fakhr Yasseri AM, Nasirian N, et al
    Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer.
    Rep Biochem Mol Biol. 2023;11:710-719.
    PubMed    
    Abstract available

  59. XIAO D, Xu S, Zhou X, Li D, et al
    Synergistic augmentation of osimertinib-induced autophagic death by proguanil or rapamycin in bladder cancer.
    MedComm (2020). 2023;4:e236.
    PubMed    


  60. RAAD E, Helou S, Hage K, Daou M, et al
    Cost of bladder cancer in Lebanon before and after the economic collapse: a probabilistic modeling study.
    Int J Equity Health. 2023;22:77.
    PubMed    
    Abstract available

  61. LIU F, Han Z, Lu J, Zhong W, et al
    Development and validation of a tobacco smoking-related index for predicting overall survival and immunotherapy response in bladder cancer.
    Environ Sci Pollut Res Int. 2023 May 2. doi: 10.1007/s11356-023-27132.
    PubMed    
    Abstract available

  62. STANIMIR M, Lorge F, D'Hondt L, Nollevaux MC, et al
    Metastasis to the penis from a bladder carcinoma invading only the lamina propria: case report and description of the morphological aspects.
    Rom J Morphol Embryol. 2023;64:89-94.
    PubMed    
    Abstract available

  63. BUKAVINA L, Bell S, Packiam VT, Smaldone M, et al
    Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
    Urol Oncol. 2023 Apr 29:S1078-1439(23)00119.
    PubMed    
    Abstract available

  64. YAN R, Shen Y, Zhang X, Xu P, et al
    Histopathological bladder cancer gene mutation prediction with hierarchical deep multiple-instance learning.
    Med Image Anal. 2023;87:102824.
    PubMed    
    Abstract available

  65. SHAHIDI M, Abazari O, Dayati P, Reza JZ, et al
    Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer.
    Nanomedicine (Lond). 2023 Apr 26. doi: 10.2217/nnm-2022-0198.
    PubMed    
    Abstract available

  66. ZHANG Z, Chen P, Yun J
    Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer.
    Front Genet. 2023;14:1156095.
    PubMed    
    Abstract available

  67. LI T, Hu W, Jin L, Yin X, et al
    Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
    Front Oncol. 2023;13:1164368.
    PubMed    
    Abstract available

  68. CHEN X, He F, Zhang W, Fu Y, et al
    Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.
    Front Oncol. 2023;13:1092969.
    PubMed    
    Abstract available

  69. HUANG H, Zhang Y, Chen Z, Zeng X, et al
    Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.
    Heliyon. 2023;9:e15157.
    PubMed    
    Abstract available

  70. SUN X, Dai T, Xu L
    Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions.
    Front Surg. 2023;10:1143219.
    PubMed    
    Abstract available

  71. GAO W, Zhang J, Tian T, Fu Z, et al
    Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
    PeerJ. 2023;11:e15284.
    PubMed    
    Abstract available

  72. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Comment on "telomerase reverse transcriptase rs2736098 and rs2736100 in bladder cancer".
    Rep Pract Oncol Radiother. 2023;28:135.
    PubMed    


  73. VANCAVAGE R, Siddiqui S, Bernstein A, Avulova S, et al
    Why has sexuality research in women with bladder cancer undergoing radical cystectomy been ignored for so long?
    J Sex Med. 2023;20:580-583.
    PubMed    


  74. DE VRIES EGE, Ruschoff J, Lolkema M, Tabernero J, et al
    Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
    Cancer Med. 2023 Apr 29. doi: 10.1002/cam4.5893.
    PubMed    
    Abstract available

  75. MA X, Zhang L, Liu L, Ruan D, et al
    Hypermethylated ITGA8 Facilitate Bladder Cancer Cell Proliferation and Metastasis.
    Appl Biochem Biotechnol. 2023 Apr 29. doi: 10.1007/s12010-023-04512.
    PubMed    
    Abstract available

  76. PARAMANANTHAM Y, B M Said NA, Mun KS
    The correlation of EMT and p53 immunohistochemical markers with cisplatin resistance in muscle invasive bladder cancer patients: A single-centred study.
    Malays J Pathol. 2023;45:19-29.
    PubMed    
    Abstract available

  77. DU C, Zheng M, Wang Z, Zhang J, et al
    Clinical characteristics and treatment outcomes of kidney transplant recipients with de novo urothelial carcinoma: thirty years of experience from a single center.
    BMC Urol. 2023;23:71.
    PubMed    
    Abstract available

  78. ZHOU L, Xu G, Huang F, Chen W, et al
    Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
    BMC Med Genomics. 2023;16:88.
    PubMed    
    Abstract available

  79. LAI HW, Yamamoto S, Fukuhara H, Ogura SI, et al
    Cell senescence-associated porphyrin metabolism affects the efficacy of aminolevulinic acid-photodynamic diagnosis in bladder cancer.
    Photodiagnosis Photodyn Ther. 2023 Apr 26:103581.
    PubMed    
    Abstract available

  80. SOBHANI S, Ghoreifi A, Douglawi A, Ahmadi H, et al
    Perioperative mortality for radical cystectomy in the modern Era: experience from a tertiary referral center.
    Int Braz J Urol. 2023;49:351-358.
    PubMed    
    Abstract available

  81. PRIJOVIC N, Santric V, Babic U, Stankovic B, et al
    Inflammatory Myofibroblastic Tumour of the Urinary Bladder in a Middle-Aged Man-A Case Report of an Unusual Localization of a Rare Tumour.
    Medicina (Kaunas). 2023;59:791.
    PubMed    
    Abstract available

  82. LUO HL, Chang YL, Liu HY, Wu YT, et al
    VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity in Upper Urinary Tract Urothelial Carcinoma.
    Int J Mol Sci. 2023;24:7486.
    PubMed    
    Abstract available

  83. QIAO L, Zhang L, Wang H
    SPAG9 Expression Predicts Good Prognosis in Patients with Clear-Cell Renal Cell Carcinoma: A Bioinformatics Analysis with Experimental Validation.
    Genes (Basel). 2023;14:944.
    PubMed    
    Abstract available

  84. KHANJANI N, Moradabadi A, Najafi E, Hayati B, et al
    Geographic variation in urinary tract and genital cancers in Iran: a hypothesis involving exposure to solar radiation.
    BMC Res Notes. 2023;16:65.
    PubMed    
    Abstract available

  85. XIAO XY, Zhao H, Guo HQ, Wang C, et al
    [Tumor cell-based glycolytic metabolism and single-cell sequencing of urinary exfoliated cells for the diagnosis and molecular profiling of urothelial carcinoma].
    Zhonghua Bing Li Xue Za Zhi. 2023;52:472-479.
    PubMed    
    Abstract available

  86. ALTINTAS TASLICAY C, Sivrioglu AK
    Urinary Bladder Masslike Lesions.
    Radiographics. 2023;43:e230012.
    PubMed    


  87. FARAG CM, Akosman S, Luu J, Haji-Momenian S, et al
    Hemoglobin, Albumin, Lymphocyte, and Platelet Count is a Significant Biomarker Surrogate for Nutritional Status to Predict Overall Survival in Patients Post-radical Cystectomy.
    Urol Pract. 2023;10:262-269.
    PubMed    
    Abstract available

  88. SHU TD, Prunty MC, Pominville R, Omil-Lima D, et al
    Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65.
    Urol Pract. 2023;10:59-65.
    PubMed    
    Abstract available

  89. ALTINTAS TASLICAY C, Cam I, Civriz AH, Kara O, et al
    18F-FDG PET-Positive Large Pelvic Granuloma Mimicking Malignant Bladder Tumor.
    Clin Nucl Med. 2023 Apr 25. doi: 10.1097/RLU.0000000000004676.
    PubMed    
    Abstract available

  90. JACKSON-SPENCE F, Toms C, O'Mahony LF, Choy J, et al
    IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
    Future Oncol. 2023;19:509-515.
    PubMed    
    Abstract available

  91. BAJORIN DF, Witjes JA, Gschwend JE, Schenker M, et al
    Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
    Future Oncol. 2023;19:413-426.
    PubMed    
    Abstract available

  92. GRIVAS P, Veeranki P, Chiu K, Pawar V, et al
    Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
    Future Oncol. 2023;19:369-383.
    PubMed    
    Abstract available

  93. GUZMAN SJ, Kleinschmidt-DeMasters BK
    Urothelial carcinoma metastases impacting the CNS: A 20-year retrospective series.
    Ann Diagn Pathol. 2023;64:152109.
    PubMed    
    Abstract available

  94. PEREZ-AIZPURUA X, Monzo-Gardiner JI, Maqueda-Arellano J, Buendia-Gonzalez E, et al
    BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours.
    Actas Urol Esp (Engl Ed). 2023;47:250-258.
    PubMed    
    Abstract available

  95. VARADI M, Nagy N, Reis H, Hadaschik B, et al
    Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
    Cancer Med. 2023;12:9041-9054.
    PubMed    
    Abstract available

  96. JIANG Y, Peng Y, Ding S, Zheng Y, et al
    Kidney-sparing surgery for distal high-risk ureteral carcinoma: Clinical efficacy and preliminary experiences in 22 patients.
    Cancer Med. 2023;12:7835-7843.
    PubMed    
    Abstract available

  97. XU YK, Bai J
    Multiple urinary bladder tumors: A case report.
    Asian J Surg. 2023;46:2221-2222.
    PubMed    


  98. DOMINGUEZ GARCIA A, Munoz Rodriguez J, Prats Lopez J, Almirall Daly J, et al
    Metabolic acidosis after ileal urinary diversion and radical cystectomy. Do we know as much as we think we do? A systematic review.
    Actas Urol Esp (Engl Ed). 2023;47:195-210.
    PubMed    
    Abstract available

  99. TERRITO A, Fontanet S, Meneghetti I, Gallioli A, et al
    Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
    Actas Urol Esp (Engl Ed). 2023;47:221-228.
    PubMed    
    Abstract available

  100. ALLAEYS C, De Backer P, Decaestecker K, Berquin C, et al
    Peritoneal tuberculosis caused by intravesical instillation with Bacillus Calmette-Guerin (BCG) following nephroureterectomy in a patient with bladder and upper tract urothelial cancer: a case report.
    Acta Clin Belg. 2023;78:257-260.
    PubMed    
    Abstract available

  101. TANG YC, Yang CS, Liang MX, Zhang Y, et al
    Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients.
    Medicine (Baltimore). 2023;102:e33719.
    PubMed    
    Abstract available

  102. SEILER R, Egger M, De Menna M, Wehrli S, et al
    Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
    BMC Urol. 2023;23:89.
    PubMed    
    Abstract available

  103. ZHANG B, Liu T, He Y, Han D, et al
    Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer.
    BMC Urol. 2023;23:91.
    PubMed    
    Abstract available

  104. ZHENG Y, Wang X, Yang X, Xing N, et al
    Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancer.
    Cell Oncol (Dordr). 2023 May 11. doi: 10.1007/s13402-023-00820.
    PubMed    
    Abstract available

  105. NURMINEN P, Nummi A, Kesti O, Ettala O, et al
    Comparison of Bacillus Calmette-Guerin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2023 May 9:S2405-4569(23)00110-4. doi: 10.1016/j.euf.2023.
    PubMed    
    Abstract available

  106. KENNELLEY GE, Amaye-Obu T, Foster BA, Tang L, et al
    Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer.
    Am J Clin Exp Urol. 2023;11:103-120.
    PubMed    
    Abstract available

  107. BAZARGANI S, Lall C, Gopireddy DR, Liu S, et al
    Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.
    Am J Clin Exp Urol. 2023;11:185-193.
    PubMed    
    Abstract available

  108. ZHANG S, Li L, Yu P, Wu C, et al
    A deep learning model for drug screening and evaluation in bladder cancer organoids.
    Front Oncol. 2023;13:1064548.
    PubMed    
    Abstract available

  109. OHTSU A, Arai S, Fujizuka Y, Fukuda R, et al
    Retroperitoneal urothelial carcinoma arising after bladder diverticulectomy: a case report.
    BMC Urol. 2023;23:88.
    PubMed    
    Abstract available

  110. HINDERBERGER P, Winters N
    Mistletoe for Bladder Cancer: Call for More Case Reports Using the Intravesical Route.
    Altern Ther Health Med. 2023;29:18-19.
    PubMed    
    Abstract available

  111. TIAN G, Li Y, Nie L, Liu S, et al
    Cervical lymph node metastasis of bladder cancer: a case report and review of literature.
    Aging Male. 2023;26:2205935.
    PubMed    
    Abstract available

  112. JIANG T, Jin P, Huang G, Li SC, et al
    The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics.
    Math Biosci Eng. 2023;20:9511-9529.
    PubMed    
    Abstract available

  113. YU J, Lee J, Ha S, Baek JW, et al
    Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
    Ann Surg Oncol. 2023 May 9. doi: 10.1245/s10434-023-13565.
    PubMed    
    Abstract available

  114. WANG L, Huang S, Zhang P, Li H, et al
    The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
    J Cancer Res Clin Oncol. 2023 May 9. doi: 10.1007/s00432-023-04739.
    PubMed    
    Abstract available

  115. HAJEBRAHIMI S, Talebpour A, Kabiri N, Ahmadian N, et al
    Promoting post-discharge telephone follow-up of patients with transurethral resection for bladder cancer: a best practice implementation project.
    JBI Evid Implement. 2023 May 10. doi: 10.1097/XEB.0000000000000374.
    PubMed    
    Abstract available

  116. REN L, Yang X, Liu J, Wang W, et al
    An innovative model based on N7-methylguanosine-related lncRNAs for forecasting prognosis and tumor immune landscape in bladder cancer.
    Cancer Cell Int. 2023;23:85.
    PubMed    
    Abstract available

  117. LUO Y, Zhang Y, Pang S, Min J, et al
    PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation.
    Mol Carcinog. 2023 May 8. doi: 10.1002/mc.23533.
    PubMed    
    Abstract available

  118. MOU Z, Chen Y, Zhang Z, Chen X, et al
    Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour-specific immunity.
    Clin Transl Med. 2023;13:e1255.
    PubMed    
    Abstract available

  119. ABUGOMAA A, Elbadawy M, Ishihara Y, Yamamoto H, et al
    Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder cancer organoids.
    Front Pharmacol. 2023;14:1159516.
    PubMed    
    Abstract available

  120. SHEN J, Hou H, Liang B, Guo X, et al
    Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Front Immunol. 2023;14:1155104.
    PubMed    
    Abstract available

  121. DU Y, Liu Y, Cao J, Jiang X, et al
    LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
    Front Immunol. 2023;14:1113756.
    PubMed    
    Abstract available

  122. ZHAO S, Wang L, Ding W, Ye B, et al
    Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Front Endocrinol (Lausanne). 2023;14:1180404.
    PubMed    
    Abstract available

  123. ANWAR M, Ejaz M, Ijaz M, Ahmad G, et al
    Association of IL-17A promoter region SNP-rs2275913 with urinary bladder cancer.
    Int J Health Sci (Qassim). 2023;17:33-38.
    PubMed    
    Abstract available

  124. REVESZ J, Posfai B, Pajor L, Papdan T, et al
    Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.
    Pathol Oncol Res. 2023;29:1611077.
    PubMed    
    Abstract available

  125. WANG H, Gao Y, Qin L, Zhang M, et al
    Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis.
    Orphanet J Rare Dis. 2023;18:107.
    PubMed    
    Abstract available

  126. LORENZO JF, Lopez Arquillo IM, Rey JV
    Primary aortoenteric fistula after intravesical instillation of Bacillus Calmette-Guerin for bladder cancer.
    Vascular. 2023 May 6:17085381231174923. doi: 10.1177/17085381231174923.
    PubMed    
    Abstract available

  127. NAIK M, Rao BV, Challa S, Fonseca D, et al
    Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
    J Cancer Res Ther. 2023;19.
    PubMed    
    Abstract available

  128. AHMAD U, Abdullah S, Chau M, Chia SL, et al
    Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.
    Sci Rep. 2023;13:7323.
    PubMed    
    Abstract available

  129. CZECH AK, Gronostaj K, Fronczek J, Frydrych J, et al
    Diagnostic accuracy of bimanual palpation in bladder cancer patients undergoing cystectomy: A prospective study.
    Urol Oncol. 2023 May 3:S1078-1439(23)00122-9. doi: 10.1016/j.urolonc.2023.
    PubMed    
    Abstract available

  130. HSIEH TY, Sung WW, Chang YC, Yu CY, et al
    Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma.
    Aging (Albany NY). 2023;15:3107-3119.
    PubMed    
    Abstract available

  131. JANA S, Brahma S, Arora S, Wladyka CL, et al
    Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
    Cancer Cell. 2023;41:853-870.
    PubMed    
    Abstract available

  132. BOLENZ C, Zengerling F
    [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].
    Urologie. 2023;62:522-524.
    PubMed    


  133. DAVIS D, Seely D, Morash C, Armstrong J, et al
    Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
    Altern Ther Health Med. 2023;29:6-17.
    PubMed    
    Abstract available

  134. ROUPRET M, Brouquet A, Colrat F, Diez-Andreu P, et al
    Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
    World J Urol. 2023;41:1069-1075.
    PubMed    
    Abstract available

  135. VAN WIJNGAARDEN C, Bus MTJ, Ruiter AEC, Lagerveld BW, et al
    A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
    World J Urol. 2023;41:1077-1083.
    PubMed    
    Abstract available

  136. DENG Y, Fu Y, Chua SL, Khoo BL, et al
    Biofilm Potentiates Cancer-Promoting Effects of Tumor-Associated Macrophages in a 3D Multi-Faceted Tumor Model.
    Small. 2023;19:e2205904.
    PubMed    
    Abstract available

  137. KE C, Hu Z, Yang C
    Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
    Cancer Med. 2023;12:9106-9115.
    PubMed    
    Abstract available

  138. MORI K, Yanagisawa T, Katayama S, Laukhtina E, et al
    Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.
    World J Urol. 2023;41:909-919.
    PubMed    
    Abstract available

  139. DICKMAN KG, Chen CH, Grollman AP, Pu YS, et al
    Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    World J Urol. 2023;41:899-907.
    PubMed    
    Abstract available

  140. MURTHY V, Maitre P, Singh M, Pal M, et al
    Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2023 May 5:S0936-6555(23)00178.
    PubMed    
    Abstract available

  141. YANG Y, Bai Y, Wang X, Guo Y, et al
    Clock gene NR1D1 might be a novel target for the treatment of bladder cancer.
    Urol Oncol. 2023 May 18:S1078-1439(23)00141.
    PubMed    
    Abstract available

  142. KUSMARTSEV S, Ku JH, Grizzi F
    Editorial: Tumor microenvironment in bladder cancer.
    Front Oncol. 2023;13:1208196.
    PubMed    


  143. WANG Y, Xie K, Chen W, Fang Y, et al
    Synergistic ferroptosis-starvation therapy for bladder cancer based on hyaluronic acid modified metal-organic frameworks.
    Bioeng Transl Med. 2023;8:e10515.
    PubMed    
    Abstract available

  144. WEINBERG MS, Zafar A, Magdamo C, Chung SY, et al
    Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer.
    JAMA Netw Open. 2023;6:e2314336.
    PubMed    
    Abstract available

  145. CHANTAPRASOPSUK S, Rees-Punia E, Patel AV
    Physical activity, obesity, and bladder cancer incidence.
    Cancer Causes Control. 2023 May 18. doi: 10.1007/s10552-023-01711.
    PubMed    
    Abstract available

  146. DAVARO F, Jain R, Li R
    Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know.
    Eur Urol Focus. 2023 May 16:S2405-4569(23)00109.
    PubMed    
    Abstract available

  147. REN D, Li L, Wang S, Zuo Y, et al
    The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells.
    Tissue Cell. 2023;82:102096.
    PubMed    
    Abstract available

  148. ZHAO F, Yang T, Zhou L, Li R, et al
    Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing beta-integrin.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  149. WARRICK JI, Al-Ahmadie H, Berman DM, Black PC, et al
    International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
    Am J Surg Pathol. 2023 May 18. doi: 10.1097/PAS.0000000000002053.
    PubMed    
    Abstract available

  150. WANG J, Shi H, Fan Z, Yang J, et al
    Prognostic nutritional index combined with NLR to construct a survival prediction model and decision analysis of patients with muscle-invasive bladder cancer after surgery.
    Cancer Med. 2023 May 18. doi: 10.1002/cam4.6088.
    PubMed    
    Abstract available

  151. DAS S, Gu L, Eve CT, Parrish J, et al
    The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
    Clin Genitourin Cancer. 2023 Apr 28:S1558-7673(23)00098.
    PubMed    
    Abstract available

  152. HEINZELBECKER J, Spieler N, Kuehn M, Fischer C, et al
    Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
    Urol Oncol. 2023 May 15:S1078-1439(23)00134.
    PubMed    
    Abstract available

  153. ZHANG C, Xiao J, Yuan T, He Y, et al
    Molecular vasculogenic mimicry-Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts.
    Front Pharmacol. 2023;14:1163115.
    PubMed    
    Abstract available

  154. SHADAB R, Nerli RB, Bidi SR, Ghagane SC, et al
    Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients.
    J Cancer Allied Spec. 2023;9:485.
    PubMed    
    Abstract available

  155. KIMURA T, Ishikawa H, Nagumo Y, Sekino Y, et al
    Efficacy and safety of Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase II trial.
    Int J Radiat Oncol Biol Phys. 2023 May 15:S0360-3016(23)00461.
    PubMed    
    Abstract available

  156. LIN J, Zhan X, Chen R, Chen T, et al
    Increased Burden of Second Bladder Cancer and Rectal Cancer in Prostate Cancer Treated With Radiotherapy: Results From Surveillance, Epidemiology, and End Results.
    Cancer Control. 2023;30:10732748231177544.
    PubMed    
    Abstract available

  157. BOU ZERDAN M, Bratslavsky G, Jacob J, Ross J, et al
    Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
    Mol Diagn Ther. 2023 May 17. doi: 10.1007/s40291-023-00647.
    PubMed    
    Abstract available

  158. VAN STRATEN CGJI, Bruins MH, Dijkstra S, Cornel EB, et al
    The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients.
    World J Urol. 2023 May 17. doi: 10.1007/s00345-023-04428.
    PubMed    
    Abstract available

  159. CELIK S, Gokbayrak O, Erol A, Yorukoglu K, et al
    Anna Karenina principle in personalized treatment of bladder cancer according to oncogram: which drug for which patient?
    Per Med. 2023 May 17. doi: 10.2217/pme-2022-0134.
    PubMed    
    Abstract available

  160. STRAUSS D, Kaplunov B, Kutikov A, Geynisman DM, et al
    Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy.
    Urol Case Rep. 2023;48:102399.
    PubMed    
    Abstract available

  161. AN MH, Kim MS, Kim C, Noh TI, et al
    Association of 5alpha-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
    JAMA Netw Open. 2023;6:e2313667.
    PubMed    
    Abstract available

  162. RELOUW S, Dugbartey GJ, Sener A
    Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer.
    Cancers (Basel). 2023;15:2381.
    PubMed    
    Abstract available

  163. LEDDEROSE S, Rodler S, Eismann L, Ledderose G, et al
    P2X1 and P2X7 Receptor Overexpression Is a Negative Predictor of Survival in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:2321.
    PubMed    
    Abstract available

  164. EL AZZOUZI M, El Ahanidi H, Hafidi Alaoui C, Chaoui I, et al
    The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer.
    Diagnostics (Basel). 2023;13:1471.
    PubMed    
    Abstract available

  165. LI X, Li L, Xiong X, Kuang Q, et al
    Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer.
    Diagnostics (Basel). 2023;13:1393.
    PubMed    
    Abstract available

  166. VANEMAN J, van Beekhuizen HJ, Boormans JL, Ewing-Graham PC, et al
    Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value.
    Virchows Arch. 2023 May 15. doi: 10.1007/s00428-023-03559.
    PubMed    
    Abstract available

  167. LINDSKROG SV, Schmokel SS, Nordentoft I, Lamy P, et al
    Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder Cancer.
    Eur Urol Open Sci. 2023;51:78-88.
    PubMed    
    Abstract available

  168. VON DEIMLING M, Mertens LS, van Rhijn BWG, Lotan Y, et al
    Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer.
    Eur Urol Open Sci. 2023;51:39-46.
    PubMed    
    Abstract available

  169. ZLOTTA AR, Ballas LK, Niemierko A, Lajkosz K, et al
    Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Lancet Oncol. 2023 May 12:S1470-2045(23)00170.
    PubMed    
    Abstract available

  170. ARAYA M, Ishikawa H, Nishioka K, Maruo K, et al
    Proton beam therapy for muscle-invasive bladder cancer: A systematic review and analysis with Proton-Net, a multicenter prospective patient registry database.
    J Radiat Res. 2023 Apr 25:rrad027. doi: 10.1093.
    PubMed    
    Abstract available

  171. BLOUDEK L, Wright P, McKay C, Derleth CL, et al
    Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC).
    Curr Oncol. 2023;30:3637-3647.
    PubMed    
    Abstract available

  172. YU J, Lee J, Ha S, Baek JW, et al
    ASO Visual Abstract: Impact of Chart-Derived Frailty Index (CFI) on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
    Ann Surg Oncol. 2023 May 15. doi: 10.1245/s10434-023-13618.
    PubMed    



  173. Chen, Y, Zhang, W, Kadier, A, Zhang, H, Yao, X. MicroRNA-769-5p suppresses cell growth and migration via targeting NUSAP1 in bladder cancer. J Clin Lab Anal. 2020; 34:e23193.
    J Clin Lab Anal. 2023 May 14:e24893. doi: 10.1002/jcla.24893.
    PubMed    


  174. ISHII M, Yamamoto Y, Yoshimura A, Hayashi T, et al
    [A Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder Showing Effectiveness of Chemotherapy with Gemcitabine and Cisplatin].
    Hinyokika Kiyo. 2023;69:107-112.
    PubMed    
    Abstract available

  175. HU B, Chen R, Jiang M, Xiong S, et al
    EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer.
    PeerJ. 2023;11:e15309.
    PubMed    
    Abstract available

  176. GU L, Guo H, Wu LX, Yuan JB, et al
    Prognostic analysis and validation of lncRNAs in bladder cancer on the basis of neutrophil extracellular traps.
    J Gene Med. 2023 May 13:e3525. doi: 10.1002/jgm.3525.
    PubMed    
    Abstract available

  177. GUDOWSKA-SAWCZUK M, Kudelski J, Olkowicz M, Mlynarczyk G, et al
    The Clinical Significance of Serum Free Light Chains in Bladder Cancer.
    J Clin Med. 2023;12:3294.
    PubMed    
    Abstract available

  178. MALKIEWICZ B, Jedrzejuk D, Gurwin A, Wilk K, et al
    Diagnostic Value of the Sentinel Lymph Node Technique in Patients with Muscle-Invasive Bladder Cancer.
    J Clin Med. 2023;12:3092.
    PubMed    
    Abstract available

  179. RYU D, Kim TM, Lee YH, Ha US, et al
    Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer.
    Int J Mol Sci. 2023;24:8418.
    PubMed    
    Abstract available

  180. SZYDLAK R, Ovreeide IH, Luty M, Zielinski T, et al
    Bladder Cancer Cells Interaction with Lectin-Coated Surfaces under Static and Flow Conditions.
    Int J Mol Sci. 2023;24:8213.
    PubMed    
    Abstract available

  181. PACKEISER EM, Engels L, Nolte I, Goericke-Pesch S, et al
    MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines.
    Int J Mol Sci. 2023;24:8136.
    PubMed    
    Abstract available

  182. GANDIN V, Hoeschele JD, Margiotta N
    Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0".
    Int J Mol Sci. 2023;24:7917.
    PubMed    
    Abstract available

  183. KUBIK A, das Virgens IPA, Szabo A, Varadi M, et al
    Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis.
    Int J Mol Sci. 2023;24:7859.
    PubMed    
    Abstract available

  184. GRANT SR, Tang L, Wei L, Foster BA, et al
    Mutation Hotspots Found in Bladder Cancer Aid Prediction of Carcinogenic Risk in Normal Urothelium.
    Int J Mol Sci. 2023;24:7852.
    PubMed    
    Abstract available

  185. MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
    Diagnostic and Prognostic Roles of Urine Nectin-2 and Nectin-4 in Human Bladder Cancer.
    Cancers (Basel). 2023;15:2565.
    PubMed    
    Abstract available

  186. NIE Z, Gao Y, Chen M, Peng Y, et al
    Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.
    Cancers (Basel). 2023;15:2487.
    PubMed    
    Abstract available

  187. WANG Z, Zhao C, Li Y, Wang J, et al
    Photostable Cascade Activatable Peptide Self-assembly on a Cancer Cell Membrane for High-Performance Identification of Human Bladder Cancer.
    Adv Mater. 2023 May 12:e2210732. doi: 10.1002/adma.202210732.
    PubMed    
    Abstract available

  188. LI TY, Zhang B, Zhang J
    A case report and literature review on primary solitary fibrous tumor of the bladder.
    Medicine (Baltimore). 2023;102:e33708.
    PubMed    
    Abstract available

  189. HABIL MR, Hein DW
    Effects of dose and human N-acetyltransferase 1 genetic polymorphism in benzidine metabolism and genotoxicity.
    Arch Toxicol. 2023;97:1765-1772.
    PubMed    
    Abstract available

  190. PENG L, Mehmud I, Meng C, Tang D, et al
    ASO Author Reflections: Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2023;30:3817-3818.
    PubMed    


  191. EGGER V, Hutterer GC, Mischinger J, Seles M, et al
    Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.
    World J Urol. 2023;41:1359-1364.
    PubMed    
    Abstract available

  192. LEE JL, Desai C, Park SH, Tsuchiya N, et al
    Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Urol Oncol. 2023;41:256.
    PubMed    
    Abstract available

  193. BUSETTO GM, Finati M, Chirico M, Cinelli F, et al
    Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    World J Urol. 2023;41:1329-1335.
    PubMed    
    Abstract available

  194. KOTERAZAWA S, Somiya S, Ito K, Haitani T, et al
    The efficacy of ultrasonography for the detection of upper tract urothelial carcinoma.
    J Med Ultrason (2001). 2023;50:197-203.
    PubMed    
    Abstract available

  195. PYCHA S, Trenti E, Mian C, Schwienbacher C, et al
    Diagnostic value of Xpert(R) BC Detection, Bladder Epicheck(R), Urovysion(R) FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
    World J Urol. 2023;41:1323-1328.
    PubMed    
    Abstract available

  196. PENG L, Mehmud I, Meng C, Tang D, et al
    ASO Visual Abstract: Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2023;30:3819.
    PubMed    


  197. PENG L, Mehmud I, Meng C, Tang D, et al
    Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2023;30:3805-3816.
    PubMed    
    Abstract available

  198. PARIMI V, Choi W, Feng M, Fong M, et al
    Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
    Histopathology. 2023;82:991-1002.
    PubMed    
    Abstract available

  199. JIN J, Li J, Peng C, Chen J, et al
    Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment.
    Anticancer Drugs. 2023;34:797-802.
    PubMed    
    Abstract available

  200. ROUMIGUIE M, Wong A, Belanger E, Wang G, et al
    Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design.
    Urol Oncol. 2023;41:254.
    PubMed    
    Abstract available

  201. MIURA H, Hatakeyama S, Tanaka T, Fujita N, et al
    Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction.
    Urol Oncol. 2023;41:254.
    PubMed    
    Abstract available

  202. MORTON E, Kaul S, Fleishman A, Korets R, et al
    Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection.
    Urol Oncol. 2023;41:255.
    PubMed    
    Abstract available

  203. MAISCH P, Koll F, Bolenz C, Chun FK, et al
    Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
    Urol Oncol. 2023;41:219-232.
    PubMed    
    Abstract available

  204. KUCKUCK EC, Hennenlotter J, Todenhofer T, Brunn LA, et al
    Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria.
    Urol Oncol. 2023;41:254.
    PubMed    
    Abstract available

  205. NEUMANN I, Borrelli M, Al Kallaa M, Parker RT, et al
    Rare periorbital, pseudocystic metastasis of squamous cell carcinoma of the bladder: Case report and review of the literature.
    Orbit. 2023;42:336-342.
    PubMed    
    Abstract available

  206. TYAGI P, Moon CH, Connell M, Ganguly A, et al
    Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging.
    Curr Oncol. 2023;30:4632-4647.
    PubMed    
    Abstract available

  207. BITAM S, Hamadache M, Hanini S
    Targeting bladder cancer with Trigonella foenum-graecum: a computational study using network pharmacology and molecular docking.
    J Biomol Struct Dyn. 2023 May 26:1-8. doi: 10.1080/07391102.2023.2217926.
    PubMed    
    Abstract available

  208. ZHAO J, Li J, Zhang R
    Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer.
    Biochim Biophys Acta Rev Cancer. 2023 May 23:188926.
    PubMed    
    Abstract available

  209. LI W, Wang Z, Jiang Z, Yan Y, et al
    MiR-3960 inhibits bladder cancer progression via targeting of DEXI.
    Biochem Biophys Res Commun. 2023;668:8-18.
    PubMed    
    Abstract available

  210. OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
    Targeted and untargeted urinary metabolic profiling of bladder cancer.
    J Pharm Biomed Anal. 2023;233:115473.
    PubMed    
    Abstract available

  211. WIRTZ HS, Hepp Z, Grewal S, Wright P, et al
    Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model.
    Am J Manag Care. 2023;29:e136-e142.
    PubMed    
    Abstract available

  212. BENABDALLAH W, Ben Othmane M, Ouahchi I, Mestiri S, et al
    Plasmacytoid bladder cancer: a rare case report.
    Ann Med Surg (Lond). 2023;85:1885-1887.
    PubMed    
    Abstract available

  213. MIRTO BF, Scafuri L, Sicignano E, Luca C, et al
    Nature's hidden gem: quercitrin's promising role in preventing prostate and bladder cancer.
    Future Sci OA. 2023;9:FSO867.
    PubMed    


  214. BAUDEWYNS A, Jabbour T, Bourgeno HA, Peltier A, et al
    Late-onset enteric fistula following radical cystectomy for bladder cancer: A case report.
    Urol Case Rep. 2023;49:102431.
    PubMed    
    Abstract available

  215. HRBACEK J, Hanacek V, Kadleckova D, Cirbusova A, et al
    Urinary shedding of common DNA viruses and their possible association with bladder cancer: a qPCR-based study.
    Neoplasma. 2023;70:311-318.
    PubMed    
    Abstract available

  216. UCHIDA H, Obinata D, Takada S, Yoshizawa T, et al
    Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer.
    J Int Med Res. 2023;51:3000605231173319.
    PubMed    
    Abstract available

  217. MAAS M, Todenhofer T, Black PC
    Urine biomarkers in bladder cancer - current status and future perspectives.
    Nat Rev Urol. 2023 May 24. doi: 10.1038/s41585-023-00773.
    PubMed    
    Abstract available

  218. HUDDART R, Hafeez S, Omar A, Alonzi R, et al
    Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
    Clin Oncol (R Coll Radiol). 2023 May 9:S0936-6555(23)00180.
    PubMed    
    Abstract available

  219. JOHANNSEN M, Klier J, Konig F, Schonfelder R, et al
    [National Registries for Urothelial Cancer (UroNAT) and Prostate Cancer (ProNAT) by d-uo].
    Aktuelle Urol. 2023;54:202-207.
    PubMed    
    Abstract available

  220. DOEHN C, Johannsen M, Eichenauer R, Klier J, et al
    [The cancer registry notification seen from the perspective of the German Society of Uro-Oncologists (d-uo)].
    Aktuelle Urol. 2023;54:189-195.
    PubMed    
    Abstract available


  221. [Not Available].
    Aktuelle Urol. 2023;54:185.
    PubMed    


  222. DE JONG FC, Laajala TD, Hoedemaeker RF, Jordan KR, et al
    Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin.
    Sci Transl Med. 2023;15:eabn4118.
    PubMed    
    Abstract available

  223. DENG Z, Dong W, Xiong S, Jin D, et al
    Machine learning models combining computed tomography semantic features and selected clinical variables for accurate prediction of the pathological grade of bladder cancer.
    Front Oncol. 2023;13:1166245.
    PubMed    
    Abstract available

  224. LONATI C, Soria F, Pradere B, D'Andrea D, et al
    Comment on: "Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG".
    Minerva Urol Nephrol. 2023;75:407-409.
    PubMed    


  225. ASERO V, Scornajenghi CM, Krajewski W, Szydelko T, et al
    Comment on: "Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma".
    Minerva Urol Nephrol. 2023;75:401-403.
    PubMed    


  226. KHODADADI F, Khorashadizadeh M, Ghasemi F
    Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer 5637 cells in vitro.
    Mol Biol Rep. 2023 May 23. doi: 10.1007/s11033-023-08472.
    PubMed    
    Abstract available

  227. DE LIMA CSA, Rial-Hermida MI, de Freitas LF, Pereira-da-Mota AF, et al
    Mucoadhesive gellan gum-based and carboxymethyl cellulose -based hydrogels containing gemcitabine and papain for bladder cancer treatment.
    Int J Biol Macromol. 2023 May 20:124957. doi: 10.1016/j.ijbiomac.2023.124957.
    PubMed    
    Abstract available

  228. LIU SS, Li JS, Xue M, Wu WJ, et al
    LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
    Int J Biol Sci. 2023;19:2599-2612.
    PubMed    
    Abstract available

  229. XIE S, He J, Feng B, Rao D, et al
    A potential biological signature of 7-methylguanosine-related lncRNA to predict the immunotherapy effects in bladder cancer.
    Heliyon. 2023;9:e15897.
    PubMed    
    Abstract available

  230. SCHELTES DA, van der Steen-Banasik EM, Smits GAHJ
    Quality of life of muscle-invasive bladder cancer patients after brachytherapy-based treatment: A cross-sectional study.
    J Contemp Brachytherapy. 2023;15:110-116.
    PubMed    
    Abstract available

  231. WANG X, Zhang Y, Wu Y, Cheng H, et al
    The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy.
    Front Immunol. 2023;14:1202633.
    PubMed    
    Abstract available

  232. LIU H, Xiang P, Miao W, Liu H, et al
    Analysis of the Regulatory Effect of ACTG2 on Biological Behavior of Bladder Cancer Cells Based on Database Screening.
    Cell Mol Biol (Noisy-le-grand). 2023;69:125-130.
    PubMed    
    Abstract available

  233. LIU H, Wang X, Guo Z, Sun G, et al
    LncRNA BCLET variant confers bladder cancer susceptibility through alternative splicing of MSANTD2 exon 1.
    Cancer Med. 2023 May 21. doi: 10.1002/cam4.6072.
    PubMed    
    Abstract available

  234. SARAVANABAVAN S, Prakash GJ, Joshi A, Pal M, et al
    Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an Indian Tertiary Care Cancer Center.
    Clin Genitourin Cancer. 2023 Apr 11:S1558-7673(23)00082.
    PubMed    
    Abstract available

  235. CHUNG R, Moran GW, Movassaghi M, Pohl D, et al
    Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy.
    Urol Oncol. 2023 May 18:S1078-1439(23)00137.
    PubMed    
    Abstract available

  236. SANYA DRA, Onesime D
    Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.
    Hum Cell. 2023 May 20. doi: 10.1007/s13577-023-00915.
    PubMed    
    Abstract available

  237. YUAN H, Xiu Y, Liu T, Fan Y, et al
    The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma.
    Front Immunol. 2023;14:1126247.
    PubMed    
    Abstract available

  238. HUA X, Li J, Shang M, He W, et al
    Pathogenesis of psoriasis via miR-149-5p/AKT1axis by long noncoding RNA BLACAT1.
    Skin Res Technol. 2023;29:e13339.
    PubMed    
    Abstract available

  239. WIECZOREK E, Wolniakowska A, Roszak J, Rodrigues RM, et al
    Gene-occupation interactions: a review of the literature on bladder and prostate cancer.
    Med Pr. 2023;74:127-144.
    PubMed    
    Abstract available

  240. TAPPERO S, Cano Garcia C, Incesu RB, Piccinelli ML, et al
    Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy.
    Surg Oncol. 2023;48:101947.
    PubMed    
    Abstract available

  241. TAN WS, Tan MY, Alhalabi O, Campbell MT, et al
    Evolving systemic management of urothelial cancers.
    Curr Opin Oncol. 2023;35:186-199.
    PubMed    
    Abstract available

  242. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Regional differences in total hospital costs for radical cystectomy in the United States.
    Surg Oncol. 2023;48:101924.
    PubMed    
    Abstract available

  243. LO YC, Bauer AH, Odintsov I, Siegmund SE, et al
    Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas.
    Mod Pathol. 2023;36:100126.
    PubMed    
    Abstract available

  244. MUSANGILE FY, Matsuzaki I, Iwamoto R, Sagan K, et al
    Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
    Mod Pathol. 2023;36:100120.
    PubMed    
    Abstract available

  245. BASU M, Mukhopadhyay D, Chakraborty B, Ghosh S, et al
    Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.
    Mol Cell Biochem. 2023;478:1599-1610.
    PubMed    
    Abstract available

  246. BRAVI CA, Piazza P, Mazzone E, Dell'Oglio P, et al
    Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-up.
    J Robot Surg. 2023;17:1143-1150.
    PubMed    
    Abstract available

  247. VISWAMBARAM P, McCombie SP, Hawks C, Wallace DMA, et al
    Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database.
    Asia Pac J Clin Oncol. 2023;19:290-295.
    PubMed    
    Abstract available

  248. YAMADA Y, Ikeda M, Hirayama T, Murakami Y, et al
    Noninferior oncological outcomes in adults aged 80 years or older compared with younger patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma.
    Asia Pac J Clin Oncol. 2023;19:305-311.
    PubMed    
    Abstract available

  249. GELLRICH AL, Eraky A, Hamann C, Hugelmann K, et al
    [Cystectomy of a young patient with squamous cell metaplasia of the bladder and manifestation of condyloma].
    Aktuelle Urol. 2023;54:223-227.
    PubMed    
    Abstract available

  250. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    PubMed    
    Abstract available

  251. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
    BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
    PubMed    


  252. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
    Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
    BJU Int. 2023;131:571-580.
    PubMed    
    Abstract available

  253. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
    Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    BJU Int. 2023;131:691-693.
    PubMed    


  254. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
    BJU Int. 2023;131:734-744.
    PubMed    
    Abstract available

  255. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
    Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    BJU Int. 2023;131:755-762.
    PubMed    
    Abstract available

  256. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
    Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
    BJU Int. 2023;131:712-719.
    PubMed    
    Abstract available

  257. CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
    Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
    Eur J Cancer. 2023;187:58-64.
    PubMed    
    Abstract available

  258. JUBBER I, Ong S, Bukavina L, Black PC, et al
    Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
    Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  259. MOSCHINI M, Montorsi F
    Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors.
    Eur Urol. 2023;83:582.
    PubMed    


  260. BAMIAS A, Stenzl A, Brown SL, Albiges L, et al
    Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
    Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  261. KOUTROS S, Kiemeney LA, Pal Choudhury P, Milne RL, et al
    Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
    Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  262. HOSSEINI B, Zendehdel K, Bouaoun L, Hall AL, et al
    Bladder cancer risk in relation to occupations held in a nationwide case-control study in Iran.
    Int J Cancer. 2023 May 9. doi: 10.1002/ijc.34560.
    PubMed    
    Abstract available

  263. LIU Z, Leow JJ, Yong DZP
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
    PubMed    


  264. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
    Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
    Int J Urol. 2023;30:471-472.
    PubMed    


  265. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
    Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
    Int J Urol. 2023;30:464-471.
    PubMed    
    Abstract available

  266. YILMAZ H, Cinar NB, Avci IE, Akdas EM, et al
    Evaluation of comprehensive complication index versus Clavien-Dindo classification in prediction of overall survival after radical cystectomy.
    Int Urol Nephrol. 2023;55:1459-1465.
    PubMed    
    Abstract available

  267. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    PubMed    
    Abstract available

  268. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    PubMed    
    Abstract available

  269. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
    PubMed    


  270. HO JN, Jeon JS, Kim DH, Ryu H, et al
    CUDC‑907 suppresses epithelial‑mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer.
    Oncol Rep. 2023;49:130.
    PubMed    
    Abstract available

  271. SOOROJEBALLY Y, Neuzillet Y, Lebret T, Allory Y, et al
    Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
    Prog Urol. 2023 Apr 21:S1166-7087(23)00083-0. doi: 10.1016/j.purol.2023.
    PubMed    
    Abstract available

  272. PASTER IC, Zeng J, Recio-Boiles A, Chipollini J, et al
    Gender, racial and ethnic differences in pathologic response following neoadjuvant chemotherapy for bladder cancer patients.
    Urology. 2023 May 23:S0090-4295(23)00446-6. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  273. WAHLEN MM, McElree IM, Packiam VT
    Editorial Comment On: Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
    Urology. 2023 May 19:S0090-4295(23)00371-0. doi: 10.1016/j.urology.2023.
    PubMed    


  274. THOMAS R, Wiley CA, Droste EL, Robertson J, et al
    Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    PLoS Genet. 2023;19:e1010575.
    PubMed    
    Abstract available


  275. Expression of Concern: The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
    PLoS One. 2023;18:e0284938.
    PubMed    


  276. HAMID ARAH, Syadza YZ, Yausep OE, Christanto RBI, et al
    The expression of stem cells markers and its effects on the propensity for recurrence and metastasis in bladder cancer: A systematic review.
    PLoS One. 2023;18:e0269214.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;